Shares of Regeneron Pharmaceuticals Inc. rose 4.94% to $517.60 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.09% to 6,005.88 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with ...

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...

Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

Still, it's been a rough time for 23andMe and its users over the past few years. The company had a major data breach, saw its valuation plummet, and is now ultimately bankrupted and up for sale.